Clinical trial NCT01887522: Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults
Official title: Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Refractory Low-grade Gliomas
Recurrent Low-grade Gliomas
Keywords: Children
Adolescents
Young Adults
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
Collaborators: name: Innovative Therapies For Children with Cancer Consortium
First posted: 2013-06-27
Enrollment: 144
Sex: ALL
Minimum age (years): 6
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multicenter, open label, prospective study including successively a phase I trial and then a phase II trial Phase I : Open label, non-randomized, sequential dose escalation of both drugs, vinblastine and nilotinib.

Detailed description: Low grade gliomas (LGG) are the most frequent brain tumor type in children. They are often chemosensitive. However, more than 50% of these tumors will progress within the first 5 years after the start of the treatment and need a second-line therapy. In most cases, patients are still young and the risk of side effects from radiation therapy will call for another medical treatment. If a tumor does not respond to first-line chemotherapy, the prognosis worsens with 25% of deaths within the first 5 years for optic gliomas. Vinblastine (Velbe®) is an effective drug for low grade gliomas with both antiproliferative and antiangiogenic effects. An update of the Canadian phase II of weekly vinblastine (6 mg/m²/week) reported one complete response (CR), three partial responses (PR) and 9 minor responses (MR) in the first 31 patients. The 1-year progressionfree survival (PFS) rate was 57%. Tolerance of the treatment is fair allowing prolonged maintenance therapy as in Langerhans cell histiocytosis and anaplastic large cell lymphoma (ALCL). These data encourage proceeding with further testing this approach in pediatric low-grade glioma.

Nilotinib is a tyrosine kinase inhibitor (TKI) known to affect c-Kit, DDR1 and the PDGF receptors alpha and beta. PDGF is a growth factor for normal and tumoral astrocytes and oligodendrocytes. In addition, PDGF receptors are expressed on pediatric low-grade glioma vessels. Tumor response to this class of TKI has been reported occasionally . When used as monotherapy, this class of TKI was well tolerated in children, including those with brain tumors. Taking advantage of their different antiangiogenic mechanisms, their limited and non-overlapping toxicities, vinblastine and nilotinib could play an interesting role in the treatment of pediatric low-grade glioma. Nilotinib via PDGFRA and c-kit interactions may also interfere with the stroma of the tumor which is a key factor for tumor growth as shown in the NF1 mouse model. Both drugs have also immunostimulating effects especially in dendritic cells, that will be explored during treatment in selected patients. Previous to the phase II assessing the efficacy of the combination compared to vinblastine as single agent, nilotinib and vinblastine have to be administered by escalating dosages in order to identify the recommended doses of each agent when given in combination. This phase I part of the trial is justified by a possible interaction of the two drugs that are substrates of cytochrome P450 CYP3A4. Initial/starting dose of nilotinib (115 mg/m² BID) will be 50% of the recommended dose when used as monotherapy in adults (800 mg/day: 400 mg BID =230 mg/m2 BID). Initial/starting dose of vinblastine will be 50% of the recommended dose when used as monotherapy or in association with other chemotherapeutic drugs (i.e. 3 mg/m2 once a week). This justifies obtaining pharmacokinetic data on both drugs when used in combination. A phase I trial evaluating nilotinib as single agent in pediatrics in hematological malignancies is ongoing, run by the ITCC and the COG group, exploring the dose-levels 230 mg/m² to 460 mg/m² BID. The results of this phase I trial, expected by 2012, and the data of the current trial will be considered to decide whether a higher dose-level for nilotinib can be opened (350 mg/m² BID).

Eligibility criteria: Inclusion Criteria:

1. Written informed consent signed by the patient, or parents or legal representative and assent of the minor child.
2. Age: 6 months to \< 21 years of age at time of study entry
3. Histologically confirmed low-grade glioma in non-NF1 patients (no further biopsy is needed at study entry). For patients with NF1, no biopsy is required to confirm the radiological diagnosis of the low grade glioma.
4. Relapse or refractory tumor after at least one first-line therapy, not taking into account surgery only.
5. Evaluable Disease on morphologic MRI
6. Karnofsky performance status score \>=70% for patients \>12 years of age, or Lansky score \>=70% for patients \<=12 years of age, including patients with motor paresis due to disease.
7. Life expectancy \>= 3 months.
8. Adequate organ function:

   * Adequate hematopoietic function: neutrophils ³1.0 x 109/L, platelets ³100 x 109/L; hemoglobin ³8 g/dL
   * Adequate renal function: serum creatinine \< 1.5 x ULN for age 0 - 1 year: \<= 40 µmol/L

     1 - 15 years: \<= 65 µmol/L 15 - 20 years: \<= 110 µmol/L In case serum creatinine \>1.5 ULN according to age, creatinine clearance has to be \>70 mL/min/1.73 m2 or glomerular filtration rate measurement \>70% of the expected value
   * Adequate electrolytes levels: potassium, magnesium, phosphor, total calcium Lower Limit of Normal (LLN)
   * Adequate hepatic function: total bilirubin \<=1.5 x ULN; AST and ALT \<=2.5 x ULN.
   * Absence of peripheral neuropathy \>= grade 2 (Common Toxicity Criteria Adverse Event, NCI CTCAE v4.0)
   * Adequate cardiac function:

   Shortening Fraction (SF) \>= 28% (35% for children \<3 years) and Left Ventricular Ejection Fraction (LVEF) \>= 50% at baseline, as determined by echocardiography

   Absence of QTc prolongation (QTc \> 450 msec on baseline ECG, using the QTcF formula) or other clinically significant ventricular or atrial arrhythmia
9. Wash-out period of at least

   * 3 weeks in case of preliminary chemotherapy,
   * 6 weeks in case of nitrosourea-containing chemotherapy,
   * 2 weeks in the case of treatment with vincristine only
   * 6 weeks in case of radiation therapy
10. Possibility of receiving the therapeutic schedule as indicated in the protocol
11. Patients with reproductive potential must use effective contraception during their treatment and for up to 90 days after the last dose. Females with reproductive potential must have a negative pregnancy test \<= 7 days before starting Nilotinib and/or Vinblastine.
12. Patients already treated with one of the two drugs can be enrolled in the trial provided that rechallenging them with the same drug could be considered acceptable

Exclusion Criteria:

1. Concomitant anti-tumor treatment
2. Not recovered to \<Grade 2 from the acute toxic effects of all prior chemotherapy, immunotherapy or radiotherapy
3. Known intolerance or hypersensitivity to Vinblastine
4. Existence of another severe systemic disease
5. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or antifungal medicines,
6. Any concurrent illness which in the opinion of the investigator may interfere with the treatment and evaluation of the patient
7. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of nilotinib.
8. Simultaneous treatment with strong cytochromes P450 CYP3A4 inhibitors (e.g. antiepileptic drugs, see complete list in the Appendix 5).
9. Simultaneous treatment with antiarrythmic drugs and other drugs known to prolong QT interval (cloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, cisapride and pimozide). A list of QT prolonging compounds can be found at http://www.azcert.org/medical-pros/druglists/drug-lists.cfm (Appendix 6)
10. Impaired cardiac function including any one of the following:

    * Clinically significant resting brachycardia (\<50 beats per minute).
    * QTc \> 450 msec on baseline ECG. If QTc \>450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc.
    * Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension).
    * History of or presence of clinically significant ventricular or atrial tachyarrhythmias (including congenital long QT syndrome or a known family history of congenital long QT syndrome)

Primary outcomes:
measure: Progression Free Survival (PFS)
timeFrame: assessed up from randomization to tumor progression or death whatever the cause assessed up to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Medical University of Vienna
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Villejuif
country: France
facility: Gustave Roussy
state: Val De Marne
city: Padua
country: Italy
facility: University Hospital of Padua
city: Rotterdam
country: Netherlands
facility: Erasmus MC/Sophia Children's Hospital
city: Barcelona
country: Spain
facility: Fundació Sant Joan de Déu
city: Bern
country: Switzerland
facility: Swiss Pediatric Oncology Group
city: Edgbaston
country: United Kingdom
facility: Cancer Research UK Clinical Trials Unit School of Cancer Sciences University of Birmingham
state: Birmingham
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Jacques GRILL, MD
role: STUDY_CHAIR
References: